Do analysts prefer CARM or EVGN?

Carisma Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 16,293.44%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts rate SDST or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stardust Power 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is SDST or EVGN more profitable?

Stardust Power has a net margin of 0.00% compared to Evogene's net margin of -638.12%. Stardust Power's return on equity of 0.00% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Stardust Power N/A N/A -161.57% Evogene -638.12% -158.82% -80.37%

Do analysts prefer SNES or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senestech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is SNES or EVGN more profitable?

Senestech has a net margin of -304.22% compared to Evogene's net margin of -638.12%. Senestech's return on equity of -67.60% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Senestech -304.22% -67.60% -49.21% Evogene -638.12% -158.82% -80.37%

Does the media refer more to SNES or EVGN?

In the previous week, Senestech had 4 more articles in the media than Evogene. MarketBeat recorded 7 mentions for Senestech and 3 mentions for Evogene. Senestech's average media sentiment score of 1.26 beat Evogene's score of 1.16 indicating that Senestech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Senestech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TSE or EVGN?

Trinseo currently has a consensus target price of $1.00, indicating a potential upside of 334.78%. Given Trinseo's higher probable upside, equities research analysts plainly believe Trinseo is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinseo 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, TSE or EVGN?

Evogene has lower revenue, but higher earnings than Trinseo. Evogene is trading at a lower price-to-earnings ratio than Trinseo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trinseo $3.13B 0.00 -$348.50M -$11.55 N/A Evogene $3.85M 1.32 -$8.48M -$1.39 N/A

Is TSE or EVGN more profitable?

Trinseo has a net margin of -13.15% compared to Evogene's net margin of -638.12%. Trinseo's return on equity of 0.00% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Trinseo -13.15% N/A -11.72% Evogene -638.12% -158.82% -80.37%

Do analysts rate EVGN or ORGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Origin Materials 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EVGN or ORGN more profitable?

Evogene has a net margin of -638.12% compared to Origin Materials' net margin of -1,742.04%. Origin Materials' return on equity of -120.66% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Evogene -638.12% -158.82% -80.37% Origin Materials -1,742.04% -120.66% -99.50%

Does the media favor EVGN or ORGN?

In the previous week, Evogene and Evogene both had 3 articles in the media. Evogene's average media sentiment score of 1.16 beat Origin Materials' score of 0.63 indicating that Evogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Origin Materials 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Evogene (EVGN) Competitors

$0.58 -0.01 (-1.20%)

Closing price 04:00 PM Eastern

Extended Trading

$0.56 -0.02 (-3.41%)

As of 07:47 PM Eastern

Compare

EVGN vs. CARM, SDST, SNES, TSE, and ORGN

Should you buy Evogene stock or one of its competitors? MarketBeat compares Evogene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evogene include Carisma Therapeutics (CARM), Stardust Power (SDST), Senestech (SNES), Trinseo (TSE), and Origin Materials (ORGN).

How does Evogene compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Carisma Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Evogene has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.02	-$60.48M	$0.73	0.01
Evogene	$3.85M	1.32	-$8.48M	-$1.39	N/A

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Evogene had 3 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 1.16 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Positive

Carisma Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 16,293.44%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -638.12%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-638.12%	-158.82%	-80.37%

Summary

Carisma Therapeutics beats Evogene on 9 of the 16 factors compared between the two stocks.

How does Evogene compare to Stardust Power?

Stardust Power (NASDAQ:SDST) and Evogene (NASDAQ:EVGN) are both small-cap chemicals companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Evogene has higher revenue and earnings than Stardust Power. Stardust Power is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stardust Power	N/A	N/A	-$15.72M	-$2.00	N/A
Evogene	$3.85M	1.32	-$8.48M	-$1.39	N/A

Stardust Power has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Evogene has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stardust Power	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Stardust Power has a net margin of 0.00% compared to Evogene's net margin of -638.12%. Stardust Power's return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stardust Power	N/A	N/A	-161.57%
Evogene	-638.12%	-158.82%	-80.37%

32.8% of Stardust Power shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 55.3% of Stardust Power shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Evogene had 1 more articles in the media than Stardust Power. MarketBeat recorded 3 mentions for Evogene and 2 mentions for Stardust Power. Stardust Power's average media sentiment score of 1.43 beat Evogene's score of 1.16 indicating that Stardust Power is being referred to more favorably in the media.

Company	Overall Sentiment
Stardust Power	Positive
Evogene	Positive

Summary

Evogene beats Stardust Power on 9 of the 14 factors compared between the two stocks.

How does Evogene compare to Senestech?

Senestech (NASDAQ:SNES) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Senestech has higher earnings, but lower revenue than Evogene. Senestech is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senestech	$2.22M	3.94	-$6.38M	-$1.89	N/A
Evogene	$3.85M	1.32	-$8.48M	-$1.39	N/A

Senestech has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Evogene has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senestech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Senestech has a net margin of -304.22% compared to Evogene's net margin of -638.12%. Senestech's return on equity of -67.60% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senestech	-304.22%	-67.60%	-49.21%
Evogene	-638.12%	-158.82%	-80.37%

5.2% of Senestech shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 2.2% of Senestech shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Senestech had 4 more articles in the media than Evogene. MarketBeat recorded 7 mentions for Senestech and 3 mentions for Evogene. Senestech's average media sentiment score of 1.26 beat Evogene's score of 1.16 indicating that Senestech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senestech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Senestech and Evogene tied by winning 7 of the 14 factors compared between the two stocks.

How does Evogene compare to Trinseo?

Trinseo (NYSE:TSE) and Evogene (NASDAQ:EVGN) are both small-cap chemicals companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Trinseo currently has a consensus target price of $1.00, indicating a potential upside of 334.78%. Given Trinseo's higher probable upside, equities research analysts plainly believe Trinseo is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinseo	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

82.7% of Trinseo shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 4.5% of Trinseo shares are held by insiders. Comparatively, 7.4% of Evogene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Evogene had 3 more articles in the media than Trinseo. MarketBeat recorded 3 mentions for Evogene and 0 mentions for Trinseo. Evogene's average media sentiment score of 1.16 beat Trinseo's score of 0.00 indicating that Evogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Trinseo	Neutral
Evogene	Positive

Trinseo has a net margin of -13.15% compared to Evogene's net margin of -638.12%. Trinseo's return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinseo	-13.15%	N/A	-11.72%
Evogene	-638.12%	-158.82%	-80.37%

Evogene has lower revenue, but higher earnings than Trinseo. Evogene is trading at a lower price-to-earnings ratio than Trinseo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinseo	$3.13B	0.00	-$348.50M	-$11.55	N/A
Evogene	$3.85M	1.32	-$8.48M	-$1.39	N/A

Trinseo has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Evogene has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

Summary

Trinseo and Evogene tied by winning 8 of the 16 factors compared between the two stocks.

How does Evogene compare to Origin Materials?

Evogene (NASDAQ:EVGN) and Origin Materials (NASDAQ:ORGN) are both small-cap chemicals companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Evogene has a net margin of -638.12% compared to Origin Materials' net margin of -1,742.04%. Origin Materials' return on equity of -120.66% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-638.12%	-158.82%	-80.37%
Origin Materials	-1,742.04%	-120.66%	-99.50%

Evogene has higher earnings, but lower revenue than Origin Materials. Evogene is trading at a lower price-to-earnings ratio than Origin Materials, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.32	-$8.48M	-$1.39	N/A
Origin Materials	$18.92M	0.32	-$249.70M	-$47.83	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Origin Materials	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.4% of Evogene shares are held by institutional investors. Comparatively, 29.9% of Origin Materials shares are held by institutional investors. 7.4% of Evogene shares are held by company insiders. Comparatively, 2.8% of Origin Materials shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Evogene and Evogene both had 3 articles in the media. Evogene's average media sentiment score of 1.16 beat Origin Materials' score of 0.63 indicating that Evogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Origin Materials	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evogene has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Origin Materials has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

Evogene beats Origin Materials on 10 of the 14 factors compared between the two stocks.

Get Evogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVGN vs. The Competition

Export

Metric	Evogene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.15M	$3.39B	$6.75B	$12.02B
Dividend Yield	N/A	2.25%	2.66%	5.61%
P/E Ratio	-0.42	19.48	24.04	24.43
Price / Sales	1.32	304.87	510.75	109.73
Price / Cash	N/A	124.89	44.01	55.64
Price / Book	0.43	8.32	10.66	6.79
Net Income	-$8.48M	$23.89M	$3.56B	$337.66M
7 Day Performance	-5.67%	0.94%	0.05%	2.08%
1 Month Performance	-23.27%	-1.16%	0.37%	3.16%
1 Year Performance	-61.59%	41.51%	22.73%	27.78%

Evogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVGN Evogene	1.5439 of 5 stars	$0.58 -1.2%	N/A	-67.3%	$5.15M	$3.85M	N/A	140	Positive News Gap Down
CARM Carisma Therapeutics	2.495 of 5 stars	$0.00 flat	$1.00 +999,900.0%	-99.1%	$4K	$10.77M	0.00	20
SDST Stardust Power	1.0283 of 5 stars	$2.25 +1.4%	N/A	-65.5%	$23.49M	N/A	N/A	N/A	Positive News Short Interest Decrease High Trading Volume
SNES Senestech	2.8471 of 5 stars	$1.64 -3.0%	N/A	-41.7%	$8.96M	$2.22M	N/A	30	Short Interest Decrease Gap Down
TSE Trinseo	N/A	$0.23 flat	$1.00 +334.8%	N/A	$8.10M	$3.13B	N/A	2,950

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVGN) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evogene (EVGN) Competitors

EVGN vs. CARM, SDST, SNES, TSE, and ORGN

How does Evogene compare to Carisma Therapeutics?

Summary

How does Evogene compare to Stardust Power?

Summary

How does Evogene compare to Senestech?

Summary

How does Evogene compare to Trinseo?

Summary

How does Evogene compare to Origin Materials?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evogene (EVGN) Competitors

EVGN vs. CARM, SDST, SNES, TSE, and ORGN

How does Evogene compare to Carisma Therapeutics?

Which has more volatility and risk, CARM or EVGN?

Which has preferable valuation and earnings, CARM or EVGN?

Do insiders & institutionals hold more shares of CARM or EVGN?

Does the media prefer CARM or EVGN?

Do analysts prefer CARM or EVGN?

Is CARM or EVGN more profitable?

Summary

How does Evogene compare to Stardust Power?

Which has stronger valuation & earnings, SDST or EVGN?

Which has more volatility and risk, SDST or EVGN?

Do analysts rate SDST or EVGN?

Is SDST or EVGN more profitable?

Do institutionals and insiders hold more shares of SDST or EVGN?

Does the media prefer SDST or EVGN?

Summary

How does Evogene compare to Senestech?

Which has better valuation and earnings, SNES or EVGN?

Which has more risk & volatility, SNES or EVGN?

Do analysts prefer SNES or EVGN?

Is SNES or EVGN more profitable?

Do insiders & institutionals believe in SNES or EVGN?

Does the media refer more to SNES or EVGN?

Summary

How does Evogene compare to Trinseo?

Do analysts recommend TSE or EVGN?

Do institutionals and insiders believe in TSE or EVGN?

Does the media refer more to TSE or EVGN?

Is TSE or EVGN more profitable?

Which has stronger earnings & valuation, TSE or EVGN?

Which has more risk and volatility, TSE or EVGN?

Summary

How does Evogene compare to Origin Materials?

Is EVGN or ORGN more profitable?

Which has better earnings & valuation, EVGN or ORGN?

Do analysts rate EVGN or ORGN?

Do institutionals and insiders believe in EVGN or ORGN?

Does the media favor EVGN or ORGN?

Which has more risk & volatility, EVGN or ORGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools